🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#EGFR exon 20 insertions is becoming more and more predictive, due to the approval of different therapeutic approaches and others that are currently under investigation. 👉Which therapeutic approaches are we talking about? To find out more click here👇 sciencedirect.com/science/articl…

In a project like #Atlas, where the amount of clinical data is high and the number of variables is very large, how important is the role of the oncologist in ensuring that the data are rigorous, orderly and qualitatively accurate? Full video 👇 biomarkersatlas.com/in-3depth-anal… #WeAreAtlas

#KRAS viral oncogene mutations have been detected in about one third of #NSCLC with p.G12C being the most common pathogenic variant. The recent development of a new class of small molecule represent a milestone for the treatment of LC patients. More info🔗sciencedirect.com/science/articl…

To stimulate, implement and share as much data and information as possible: an investment for the present and for the future of scientific research. Let's explore together with Dr. Domenico Galetta what it means to be part of the Atlas #network. Full video at 👉biomarkersatlas.com/in-3depth-anal…

Not only a practical, inclusive and integrated tool to interpret and understand the lung neoplasms diagnostic and therapeutic complexity, #Atlas is much more. Let's explore together with👉 Dott.ssa Sara why is Atlas indispensable. Full video at👉biomarkersatlas.com/in-3depth-anal…

#ESMO24: Presented studies add to knowledge about the role of #LiquidBiopsy, particularly #ctDNA, in early-stage #NSCLC. Umberto Malapelle provides insights in an editorial #ESMODailyReporter 👉ow.ly/c5x150TnrjT

Sharing knowledge between experts is the pillar on which scientific progress is based. Together, we continue to look forward, working every day to make our discoveries available to everyone, but above all, to turn them into concrete solutions for everyone's health #WeAreAtlas

Liquid biopsies are a less invasive option than tissue biopsies Join Umberto Malapelle to learn about the emerging role of liquid biopsy in precision oncology, focusing on NSCLC, breast cancer, and CRC Watch here: ow.ly/Egr950TzRlM Supported by an IME Grant from Bayer

Fostering innovation through knowledge and expertise sharing! Here are some more #scientific contributions: discoveries and results obtained through collaboration between health professionals from the 20 National Institutes of the Atlas network. Umberto Malapelle | Giancarlo Troncone

#AIOM2024 has just ended! It was a valuable opportunity to take a review of the evolution of the project, talk about future study projects and much more. Below is an overview of the contributions presented and discussed at the most important national and international congresses.

The advancement of knowledge is only possible by continuing to search for concrete answers to provide new #targeted, #customised and #effective solutions. Biomarkers Atlas:🎯𝗢𝗻𝗴𝗼𝗶𝗻𝗴 𝗣𝗿𝗼𝗷𝗲𝗰𝘁𝘀 #WeAreAtlas 👉🔗biomarkersatlas.com Umberto Malapelle Giancarlo Troncone

At Biomarkers Atlas, we are committed to promoting scientific progress through knowledge acquisition and sharing. Our recent work has shown that it is crucial to avoid fragmenting analysis pathways and to prefer the use of simultaneous characterisation for all relevant markers.

A #platform that is able to bring together a range of individually very important information and bring together multi-professionality in the service of research and in the service of communities. Register on Biomarkersatlas.com and join us biomarkersatlas.com #WeAreAtlas

📌Our Scientific Secretary, Umberto Malapelle at the European Parliament, collaborating with Cancer Patient Europe and European Parliament members to enhance the use of 🩸liquid biopsy in patients with breast cancer and other solid tumors. #liquidbiopsy #EuropeanParliament

3 reasons to join Atlas Insight by Prof. #SilviaNovello Full Professor of Medical Oncology at the Department of Oncology at Università di Torino and Head of Medical Oncology at Azienda Ospedaliera Universitaria San Luigi di Orbassano. Watch full video here biomarkersatlas.com/in-3depth-anal… #WeAreAtlas

We are excited to announce the birth of the ATLAS Foundation! Our goal is to promote collaboration between biological, biomedical, medical and pharmacological research by promoting innovative solutions with the patient at the centre of the processes. pharmastar.it/news/oncoemato…

ATLAS Foundation: Breaking news🖋️📝 Out now on PharmaStar TV the full interview of Dr. Domenico Galetta (Domenico Galetta), President of the ATLAS Foundation. 👇Click on the preview to access it 👇 youtube.com/watch?v=97_i54… #WeAreAtlas

Proud to be part of this international group of collegues! "Widespread adoption of NGS may enable more efficient use of limited healthcare resources." pubmed.ncbi.nlm.nih.gov/40052485/

🧬Synergy between research and clinical practice🔬 The ATLAS Foundation is also mentioned on Repubblica📝 Click on the following link to access the full article🔗 repubblica.it/salute/dossier… #WeAreAtlas Domenico Galetta | Umberto Malapelle

🧬 Brilliant take of Umberto Malapelle on biomarker detection rates, treatment impact, and adoption across Europe using CGP vs. single-gene testing in lung cancer 🔬 Precision oncology starts with diagnostic accuracy and timely testing 📊 #LCSM #ELCC25 #CGP #Biomarkers